These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 2499702)
21. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955 [TBL] [Abstract][Full Text] [Related]
22. Optimal management of methotrexate intoxication in a child with osteosarcoma. Peyriere H; Cociglio M; Margueritte G; Vallat C; Blayac JP; Hillaire-Buys D Ann Pharmacother; 2004 Mar; 38(3):422-7. PubMed ID: 14970366 [TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution. Zhang W; Zhang Q; Tian X; Zhao H; Lu W; Zhen J; Niu X Chin Med J (Engl); 2015 Jan; 128(1):111-8. PubMed ID: 25563323 [TBL] [Abstract][Full Text] [Related]
24. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. Bacci G; Loro L; Longhi A; Bertoni F; Bacchini P; Versari M; Picci P; Serra M Anticancer Drugs; 2006 Apr; 17(4):411-5. PubMed ID: 16549998 [TBL] [Abstract][Full Text] [Related]
25. Daily profiles of plasma phenylalanine and tyrosine in patients with osteogenic sarcoma during treatment with high-dose methotrexate-citrovorum rescue. Hilton MA; Bertolone S; Patel CC Med Pediatr Oncol; 1989; 17(4):265-70. PubMed ID: 2787470 [TBL] [Abstract][Full Text] [Related]
26. [Neo-adjuvant therapy in childhood osteogenic sarcoma: a pilot study of selective postoperative chemotherapy based on response to preoperative high-dose methotrexate]. Sasaki K; Matsuoka H; Murakami T; Fujimoto T; Takayanagi F; Sawai K; Niwa J; Hara K Gan To Kagaku Ryoho; 1986 May; 13(5):1837-45. PubMed ID: 3486634 [TBL] [Abstract][Full Text] [Related]
27. 7-Hydroxy-methotrexate and clinical toxicity following high-dose methotrexate therapy. Erttmann R; Bielack S; Landbeck G J Cancer Res Clin Oncol; 1985; 109(1):86-8. PubMed ID: 3855853 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Pignon T; Lacarelle B; Duffaud F; Guillet P; Catalin J; Durand A; Monjanel S; Favre R Cancer Chemother Pharmacol; 1994; 33(5):420-4. PubMed ID: 8306417 [TBL] [Abstract][Full Text] [Related]
29. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068 [TBL] [Abstract][Full Text] [Related]
30. The influence of high-dose methotrexate therapy on serum iron. Schalhorn A; Wilmanns W; Koczorek GE Klin Wochenschr; 1986 May; 64(10):475-80. PubMed ID: 3459938 [TBL] [Abstract][Full Text] [Related]
33. [Controlled ultra-high dosage methotrexate therapy in three patients with metastatic osteosarcoma (author's transl)]. Leber H; Kotz R; Chiari K; Endler T; Gabl F; Krisch K; Salzer-Kuntschik M Wien Klin Wochenschr; 1981 Apr; 93(7):236-40. PubMed ID: 7020262 [TBL] [Abstract][Full Text] [Related]
34. Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs. Bacci G; Ferrari S; Picci P; Zolezzi C; Gherlinzoni F; Iantorno D; Cazzola A J Chemother; 1996 Dec; 8(6):472-8. PubMed ID: 8981189 [TBL] [Abstract][Full Text] [Related]
35. Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination. Bain E; Birhiray RE; Reeves DJ Ann Pharmacother; 2014 Feb; 48(2):292-6. PubMed ID: 24259648 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Widemann BC; Schwartz S; Jayaprakash N; Christensen R; Pui CH; Chauhan N; Daugherty C; King TR; Rush JE; Howard SC Pharmacotherapy; 2014 May; 34(5):427-39. PubMed ID: 24132809 [TBL] [Abstract][Full Text] [Related]
37. A Previously Unknown Drug-Drug Interaction Is Suspected in Delayed Elimination of Plasma Methotrexate in High-Dose Methotrexate Therapy. Ishizaki J; Nakano C; Kitagawa K; Suga Y; Sai Y Ann Pharmacother; 2020 Jan; 54(1):29-35. PubMed ID: 31416331 [No Abstract] [Full Text] [Related]
38. [Compatibility and toxicity of methotrexate in the treatment of bone tumors]. Pongracz N; Kelaridis T; Ritschl P Arzneimittelforschung; 1987 Apr; 37(4):456-60. PubMed ID: 3496891 [TBL] [Abstract][Full Text] [Related]
39. Effect of charcoal hemoperfusion for removal of plasma methotrexate in a patient with acute renal failure. Nemoto T; Imai C; Kaneko U; Takachi T; Iwabuchi H; Tanaka A; Nakamura G; Ogose A; Uchiyama M Pediatr Hematol Oncol; 2009; 26(7):520-5. PubMed ID: 19863208 [TBL] [Abstract][Full Text] [Related]
40. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue. Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]